Loyal’s LOY-002 Trial Targets Longer, Healthier Dog Lifespans
Edited by Debra John — February 3, 2026 — Lifestyle
This article was written with the assistance of AI.
References: newatlas
Biotech company Loyal has been running the STAY study, a large clinical trial of its life-extending drug 'LOY-002' for senior dogs, featuring a daily beef-flavored pill designed to promote healthier aging and dog lifespans. The study followed encouraging results from LOY-001, which focused on large-breed dogs, and moved to include almost all dog sizes. In April 2025, the trial marked a major milestone when Winston, a 10-year-old Miniature Dachshund from Indiana, became the 1,000th participant.
LOY-002 works by inhibiting overexpression of IGF-1, a hormone associated with cell growth and longevity pathways. Earlier LOY-001 data convinced the U.S. Food and Drug Administration’s Center for Veterinary Medicine that the drug showed a “reasonable expectation of effectiveness” in extending healthy lifespan by reducing age-related disease. With Winston’s enrollment, the STAY study became the largest clinical trial in veterinary history, and Loyal continues to recruit additional dogs, reflecting consumers’ willingness to invest in proactive wellness and evidence-based interventions for their pets.
Image Credit: Shutterstock / Eric Isselee
LOY-002 works by inhibiting overexpression of IGF-1, a hormone associated with cell growth and longevity pathways. Earlier LOY-001 data convinced the U.S. Food and Drug Administration’s Center for Veterinary Medicine that the drug showed a “reasonable expectation of effectiveness” in extending healthy lifespan by reducing age-related disease. With Winston’s enrollment, the STAY study became the largest clinical trial in veterinary history, and Loyal continues to recruit additional dogs, reflecting consumers’ willingness to invest in proactive wellness and evidence-based interventions for their pets.
Image Credit: Shutterstock / Eric Isselee
Trend Themes
-
Pet Longevity Supplements — The increase in demand for evidence-based interventions like Loyal’s LOY-002 highlights a growing market for pet longevity supplements.
-
Veterinary Clinical Trials Expansion — As Loyal's extensive clinical trial for LOY-002 demonstrates, veterinary clinical trials are expanding beyond human health into pet wellness.
-
Hormone-modulating Pharmaceuticals — The development of drugs like LOY-002 that modulate hormones for longevity presents a transformative shift in pharmaceutical approaches to aging.
Industry Implications
-
Pet Healthcare Industry — The burgeoning pet healthcare industry is being reshaped by innovations in lifespan-extending products, highlighting opportunities for new therapeutic categories.
-
Biotechnology Sector — Biotechnology's role is expanding as companies like Loyal explore new pathways for health and longevity in non-human species.
-
Veterinary Pharmaceuticals — Veterinary pharmaceuticals are experiencing disruption with targeted longevity drugs, reflecting a shift towards individualized pet health solutions.
8.3
Score
Popularity
Activity
Freshness
